Related Experiment Video
Updated: Dec 29, 2025
06:26
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
1.7K
Nanopharmaceuticals: A focus on their clinical translatability
Sofia Bisso1, Jean-Christophe Leroux1
1Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
International Journal of Pharmaceutics
|February 5, 2020
Summary
Nanoscale materials offer advanced drug delivery by modifying pharmacokinetics and biodistribution. Further research is needed to overcome challenges and translate nanomedicines into clinical practice.
Area of Science:
- Biomedical Engineering
- Materials Science
- Pharmaceutical Sciences
Background:
- Nanoscale materials are revolutionizing drug delivery, overcoming limitations of conventional therapies.
- Particulate carriers can be engineered to optimize drug half-life, biodistribution, and release kinetics for patient benefit.
Purpose of the Study:
- To review the advantages and challenges of nanopharmaceuticals.
- To discuss current nanotechnological approaches and their clinical translation.
- To identify opportunities for advancing nanomedicines.
Main Methods:
- Literature review of nanopharmaceutical research and clinical trials.
- Analysis of existing nanomedicine market approvals.
- Examination of clinical successes, failures, and trends.
Main Results:
- Approximately 50 nanoformulations are currently marketed (excluding biologics).
- Significant challenges remain in translating nanomedicines to widespread clinical use.
- Various nanotechnological strategies have shown promise but require further development.
Conclusions:
- A product-oriented research approach is crucial for nanomedicine advancement.
- Addressing current hurdles will accelerate the clinical translation of nanopharmaceuticals.
- Continued innovation in nanomedicine holds significant therapeutic potential.
Related Concept Videos
01:28Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
01:11Clinical Trials: Overview
4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
114
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
114
01:16Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
01:26Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
118
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
118